Metformin has influence on the number of variables in the insulin resistance syndrome (including coagulation and fibrinolysis) with significant lowering of the antifibrinolitic factor – plasminogen activator inhibitor–1. In overweight patient metformin is a treatment of choice in Type 2 diabetes.